C. Donawho

发表

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

Yan Shi, S. C. Panchal, Eric F. Johnson, 2015, Molecular Cancer Research.

Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families

K. Glaser, S. Davidsen, C. Tse, 2012, Journal of Pharmacology and Experimental Therapeutics.

Effect of ultraviolet-B radiation on the in vivo growth of murine melanoma cells.

I. Fidler, M. Kripke, C. Romerdahl, 1988, Cancer research.

The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Anticancer research.

Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks

Eric F. Johnson, X. Liu, V. Giranda, 2008, Molecular Cancer Research.

Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig

T. Ghayur, Jieyi Wang, Matthew M. Staron, 2017, Protein & Cell.

ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors

P. Ellis, X. Liu, V. Giranda, 2009, Clinical Cancer Research.

An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.

P. Ellis, X. Liu, V. Giranda, 2008, Analytical biochemistry.

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

S. C. Panchal, Mikkel A. Algire, P. Ellis, 2018, Molecular Cancer Research.

The RTK inhibitor, ABT-869 alone or in combination with various cytotoxic therapies demonstrate significant tumor growth inhibition in orthotopic hepatocellular carcinoma, renal cell carcinoma and prostate xenografts

S. Davidsen, J. O'Connor, Baole Wang, 2007 .

Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605

S. Davidsen, Eric F. Johnson, N. Soni, 2009, BMC Cancer.

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

M. Maitland, M. Ratain, R. Kurzrock, 2018, British Journal of Cancer.

Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.

L. Lam, Xin Lu, S. Rosenberg, 2017, Cancer research.

Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor

Qian Zhang, L. Tucker, Jieyi Wang, 2008, Proceedings of the National Academy of Sciences.

Effect of psoralen plus ultraviolet A radiation on in vivo growth of melanoma cells.

M. Kripke, C. Donawho, F. Aubin, 1991, Cancer research.

Evidence that the local effect of ultraviolet radiation on the growth of murine melanomas is immunologically mediated.

M. Kripke, C. Donawho, 1991, Cancer research.

Analysis of the protective effect of different sunscreens on ultraviolet radiation-induced local and systemic suppression of contact hypersensitivity and inflammatory responses in mice.

M. Kripke, P. Wolf, C. Donawho, 1993, The Journal of investigative dermatology.

Empowering therapeutic antibodies with IFN-α for cancer immunotherapy

Tzu-Hsuan Huang, A. Shoemaker, U. Ladror, 2019, PloS one.

Immunologic factors in melanoma.

M. Kripke, C. Donawho, 1992, Clinics in dermatology.

Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efﬁ cacy in Combination with Immune Checkpoint Blockade

Salem, P. Ellis, J. Leverson, 2020 .

Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms.

C. Bucana, I. Fidler, C. Donawho, 2002, Clinical & experimental metastasis.

Molecular characterization of new melanoma cell lines from C3H mice induced by ethanol plus ultraviolet radiation.

A. Multani, S. Pathak, C. Donawho, 2003, Cancer research.

Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.

K. Glaser, C. Tse, M. Michaelides, 2012, Bioorganic & medicinal chemistry letters.

Lack of correlation between UV‐induced enhancement of melanoma development and local suppression of contact hypersensitivity

M. Kripke, C. Donawho, 1992, Experimental dermatology.

Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization

K. Glaser, S. Fesik, Mark G. Anderson, 2010, Proceedings of the National Academy of Sciences.

Preclinical Chemosensitization by PARP Inhibitors

D. Shalinsky, C. Donawho, G. Los, 2015 .

Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152

K. Glaser, O. Shah, P. Tapang, 2009, The Pharmacogenomics Journal.

Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.

Eric F. Johnson, X. Liu, V. Giranda, 2010, Journal of medicinal chemistry.

Photoimmunology of experimental melanoma

M. Kripke, C. Donawho, 1991, Cancer and Metastasis Reviews.

Induction of Primary Cutaneous Melanomas in C3H Mice by Combined Treatment with Ultraviolet Radiation, Ethanol and Aloe Emodin¶

C. Bucana, L. Stephens, H. Muller, 2000, Photochemistry and photobiology.

Specific immunotherapy against occult cancer metastases

I. Fidler, C. Donawho, Z. Dong, 2002, International journal of cancer.

ABT-888 , an OrallyActive Poly ( ADP-Ribose ) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in PreclinicalTumorModels

Eric F. Johnson, T. DeWeese, X. Liu, 2007 .

Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.

P. Ellis, Eric F. Johnson, X. Liu, 2012, Bioorganic & medicinal chemistry.

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Eric F. Johnson, T. DeWeese, X. Liu, 2007, Clinical Cancer Research.

Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Bioorganic & medicinal chemistry.

Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent.

Eric F. Johnson, X. Liu, V. Giranda, 2008, Bioorganic & medicinal chemistry letters.

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2009, Journal of medicinal chemistry.

The immune system in ultraviolet carcinogenesis.

M. Kripke, C. Nishigori, D. Yarosh, 1996, The journal of investigative dermatology. Symposium proceedings.

Enhanced growth of murine melanoma in ultraviolet-irradiated skin is associated with local inhibition of immune effector mechanisms.

C. Bucana, M. Kripke, H. Muller, 1996, Journal of immunology.

Effect of sunscreens on UV radiation-induced enhancement of melanoma growth in mice.

M. Kripke, P. Wolf, C. Donawho, 1994, Journal of the National Cancer Institute.

Molecular regulation of UVB-induced cutaneous angiogenesis.

C. Bucana, I. Fidler, M. Kripke, 1998, The Journal of investigative dermatology.

Principles of Chemotherapy and Pharmacology

A. Shoemaker, C. Donawho, J. Palma, 2007 .

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody

A. Scott, A. Phillips, E. DiGiammarino, 2015, Molecular Cancer Therapeutics.

Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.

K. Glaser, S. Davidsen, C. Tse, 2011 .

Active specific immunotherapy against occult brain metastasis.

C. Bucana, I. Fidler, C. Donawho, 2003, Cancer research.

Active Specific Immunotherapy against Occult Brain Metastasis 1

C. Bucana, I. Fidler, C. Donawho, 2003 .

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

K. Glaser, S. Davidsen, Eric F. Johnson, 2005, Molecular Cancer Therapeutics.

Induction of Primary Cutaneous Melanomas in C3H Mice by Combined Treatment with Ultraviolet Radiation, Ethanol and Aloe Emodin ¶

C. Bucana, L. Stephens, H. Muller, 2000 .

Rationale for the combination of veliparib with platinum-based chemotherapy.

Eric F. Johnson, T. Penning, E. DiGiammarino, 2015 .

246 PARP inhibitors trap PARP1 onto damaged DNA via catalytic inhibition and not by an allosteric mechanism

Eric F. Johnson, E. DiGiammarino, L. Solomon, 2014 .

Abstract 2734: Veliparib (ABT-888) potentiates the cytotoxic activity of DNA alkylating agents by trapping PARP onto damaged chromatin

P. Ellis, Eric F. Johnson, G. Fang, 2014 .

The BCL-2-Selective Inhibitor Venetoclax Spares Activated T-Cells during Anti-Tumor Immunity

P. Ellis, J. Leverson, T. Uziel, 2018, Blood.

Evidence for the causal role of endogenous interferon-α/β in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms

C. Bucana, I. Fidler, C. Donawho, 2004, Clinical & Experimental Metastasis.

Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.

M. Ross, C. Balch, A. Buzaid, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Persistence of immunogenic pulmonary metastases in the presence of protective anti-melanoma immunity.

M. Kripke, C. Donawho, M. Pride, 2001, Cancer research.

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

John E. Harlan, Ramesh Iyer, Yan Shi, 2011, Clinical Cancer Research.

ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition

P. Ansell, Mark G. Anderson, Qian Zhang, 2021, BMC Cancer.

Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.

P. Ellis, Eric F. Johnson, N. Soni, 2009, Journal of medicinal chemistry.

Pharmacodynamic Evaluation of Irinotecan Therapy by FDG and FLT PET/CT Imaging in a Colorectal Cancer Xenograft Model

M. Day, P. Tapang, G. Fox, 2012, Molecular Imaging and Biology.

Immunogenicity and cross-reactivity of syngeneic murine melanomas.

M. Kripke, C. Donawho, 1990, Cancer communications.

Venetoclax increases intra-tumoral effector T cells and anti-tumor efficacy in combination with immune checkpoint blockade.

P. Ellis, J. Leverson, T. Uziel, 2020, Cancer Discovery.

Mechanistic Dissection of PARP 1 Trapping and the Impacton InVivo TolerabilityandEf fi cacyofPARP Inhibitors

Eric F. Johnson, J. Wilsbacher, E. DiGiammarino, 2015 .

Cancer Therapy : Preclinical Iniparib Nonselectively Modi fi es Cysteine-Containing Proteins in TumorCells and IsNot a Bona Fide PARP Inhibitor

P. Ellis, Eric F. Johnson, N. Soni, 2012 .

Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor

Qian Zhang, L. Tucker, Jieyi Wang, 2008, Proceedings of the National Academy of Sciences.

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

Eric F. Johnson, X. Liu, V. Giranda, 2009, Journal of medicinal chemistry.